STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more U.S. will require PBMs to tell their clients all the different ways they get paid Manage alerts for this article Save this story for later Share this article By Ed SilvermanOct. 30, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation.

He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. And so, another working week will soon draw to a close. Not a moment too soon, yes?

This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We will manicure the Pharmalot grounds, catch up on our reading, and mosey about town.

We also hope to hold yet another listening party, where the rotation will likely include this, this, this, this and this. And what about you? Not to sound too dramatic, but this will be your last chance to find the Great Pumpkin, so give it your best shot.

And if you live on this side of the pond, this may also be your final opportunity to decide how to cast your vote in the upcoming election — best of luck sorting out the truth. Otherwise, this may be a fine time to curl up with a book, binge-watch something on the telly, or cook a yummy meal. Well, whatever you do, have a grand time.

But be safe. Enjoy, and see you soon. … AstraZeneca has launched a three-year cost-cutting program that aims to slice off $1.5 billion a year, with the savings reinvested in R&D, Pharmaphorum writes.

There’s no word yet on the job implications from the initiative, which the company estimates will carry a one-time charge of around $2 billion and is expected to be completed by the end of 2029. The drug maker is already facing headwinds from the loss of patent protection for some products, including diabetes blockbuster Farxiga, with a string of other big brands due to lose exclusivity between now and the mid-2030’s, including three cancer drugs.Advertisement Indian regulators ordered Sun Pharmaceutical to stop manufacturing, selling and distributing ophthalmic products made at its Assam facility after finding failure in ​its quality management system, Reuters reported. The Central Drugs Standard Control Organization and the office of Drugs Controller Assam ordered the shutdown on ‌Aug.

20 after a joint federal-state inspection identified lapses in the system meant to ensure product quality and safety, following Sun Pharma’s move in July to voluntarily recall about 11 eye-care brands. Sun Pharma had previously said the site was expected to become one of its largest manufacturing ⁠hubs for sterile products in a business identified as a key global growth driver. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In pharmalittle, STAT Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation.

He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot October 29, 2026 STAT Plus: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more Pharmalot October 28, 2026 STAT Plus: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings Advertisement Pharmalot October 28, 2026 STAT Plus: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more Pharmalot October 27, 2026 STAT Plus: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts Pharmalot October 27, 2026 STAT Plus: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more Subscriber Picks